Clinical Trial Update: Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a triple combination of mezigdomide, carfilzomib, and dexamethasone for relapsed or refractory multiple myeloma with extramedu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Kyprolis (carfilzomib)
• Mezigdomide (mezigdomide)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Extramedullary Disease in Multiple Myeloma, Recurrent Multiple Myeloma | Phase 2 | Status: RECRUITING